BBIO
CONGRESS BUYBridgeBio Pharma, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Viking Global | SC 13D/A | −2.1M | 5.0% | -27.1% vs SPY -24.3% abs | 2026-07-10 | ↗ |
| Viking Global | SC 13D/A | — | 6.1% | — | 2026-04-02 | ↗ |
| Viking Global | SC 13D/A | — | 6.8% | — | 2026-02-17 | ↗ |
Tracked Funds Holding (2)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Viking Global | Andreas Halvorsen | 9.8M | $644M |
| Point72 | Steve Cohen | 602K | $40M |
Quarter-end 13F positions for the tracked funds holding this stock.
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Gilbert Cisneros | house | CA31 | BUY | $1,001 - $15,000 | 2026-11-02 | 2026-11-10 | ↗ |
| Gilbert Cisneros | house | CA31 | BUY | $1,001 - $15,000 | 2026-10-27 | 2026-11-10 | ↗ |
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Jul 1, 2026.